アクセス数 : ?
ダウンロード数 : ?
ID 114732
著者
Hirai, Shota Tokushima University
吉田, 達貞 Nagasaki International University KAKEN研究者をさがす
Maoka, Takashi Research Institute for Production Development
キーワード
antioxidant
astaxanthin
capsaicin
liposome
intermolecular interaction
stereochemistry
資料タイプ
学術雑誌論文
抄録
Our previous study reported that co-encapsulation of potent antioxidants astaxanthin (Asx) and capsaisin (Cap) into liposomes brought about synergistically higher antioxidative activity than the calculated additive activity of each single antioxidant encapsulating liposome. Based on the previous computational chemistry analysis, the synergistic effect was revealed to be resulted from intermolecular interactions between Asx, especially 3R,3′R-form of Asx stereoisomer (Asx-R), and Cap, by which changes of electronic states of the polyene moiety of Asx-R were induced. Although liposomes co-encapsulating Asx-R and Cap (Asx-R/Cap-Lipo) at an optimal ratio clearly showed synergistic antioxidative activity in vitro, it is unclear whether the effective antioxidative activity derived from intermolecular interaction between Asx-R and Cap is also exerted in vivo. Therefore, in this study, we investigated therapeutic potential of Asx-R/Cap-Lipo as an antioxidant formulation in vivo. For this purpose, we employed carbon tetrachloride (CCl4)-induced acute liver injury rat model, since CCl4 is known to cause oxidative damage in liver. CCl4 administration significantly increased the levels of aspartate transaminase (AST) and alanine aminotransferase (ALT). Intravenous combined administration of liposomes encapsulating Asx-R (Asx-R-Lipo) and liposomes encapsulating Cap (Cap-Lipo) significantly decreased CCl4-induced increase of AST and ALT levels. Importantly, the treatment with Asx-R/Cap-Lipo tended to show higher protective effect on acute liver injury than combined treatment with Asx-R-Lipo plus Cap-Lipo. These results suggest that co-encapsulated Asx-R and Cap in liposomal membranes could exert more effective antioxidative activities in vivo, and that Asx-R/Cap-Lipo would be a hopeful antioxidant formulation for treating reactive oxygen species-related diseases.
掲載誌名
Biological and Pharmaceutical Bulletin
ISSN
09186158
13475215
cat書誌ID
AA10885497
AA11696048
出版者
The Pharmaceutical Society of Japan
43
8
開始ページ
1272
終了ページ
1274
発行日
2020-08-01
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
薬学系